title: Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines.
abstract: The inability of antibodies induced by experimental human immunodeficiency virus type 1 (HIV-1) vaccines to neutralize HIV-1 primary isolates may be due to a failure to elicit such antibodies, antigenic differences between the vaccine and the strains tested, insensitivity of the assays used, or to a combination of factors. New neutralization assays were used to determine the ability of candidate AIDS vaccines to generate neutralizing antibodies for clade B primary isolate BZ167, which is closely related in portions of its envelope to the immunizing strains. Sera from HIV-uninfected volunteers in vaccine trials were tested, and neutralizing activity was found in recipients of recombinant (r) gp120MN or of rgp160MN-containing canarypox boosted with rgp120SF-2. Detection of antibodies that neutralize primary isolate BZ167 correlated with neutralizing activity for homologous vaccine strains. These data demonstrate that certain candidate AIDS vaccines can elicit antibodies that neutralize a primary isolate of HIV-1.
authors.affiliation: VA Medical Center, New York, NY 10010, USA.
authors.forename: S
authors.initials: S
authors.lastname: Zolla-Pazner
authors.forename: C
authors.initials: C
authors.lastname: Alving
authors.forename: R
authors.initials: R
authors.lastname: Belshe
authors.forename: P
authors.initials: P
authors.lastname: Berman
authors.forename: S
authors.initials: S
authors.lastname: Burda
authors.forename: P
authors.initials: P
authors.lastname: Chigurupati
authors.forename: M L
authors.initials: ML
authors.lastname: Clements
authors.forename: A M
authors.initials: AM
authors.lastname: Duliege
authors.forename: J L
authors.initials: JL
authors.lastname: Excler
authors.forename: C
authors.initials: C
authors.lastname: Hioe
authors.forename: J
authors.initials: J
authors.lastname: Kahn
authors.forename: M J
authors.initials: MJ
authors.lastname: McElrath
authors.forename: S
authors.initials: S
authors.lastname: Sharpe
authors.forename: F
authors.initials: F
authors.lastname: Sinangil
authors.forename: K
authors.initials: K
authors.lastname: Steimer
authors.forename: M C
authors.initials: MC
authors.lastname: Walker
authors.forename: N
authors.initials: N
authors.lastname: Wassef
authors.forename: S
authors.initials: S
authors.lastname: Xu
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D005260:Female; D015483:HIV Antibodies / Q000097:blood*; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120